

Client #:99999
Doctor:Sample Doctor
Sample Clinic
1234 Main St
Saint Charles, IL 60174 U.S.A.

Patient:SAMPLE PATIENT

ld:9999999


**Age:**62 **DOB:**01/12/1957

Sex: Male

Sample Collection Date/Time
Date Collected 09/23/2019
Date Received 09/26/2019
Date Reported 10/10/2019
Specimens Collected 2


#### Microbiome Abundance and Diversity Summary

The abundance and diversity of gastrointestinal bacteria provide an indication of gastrointestinal health, and gut microbial imbalances can contribute to dysbiosis and other chronic disease states. The Gl360  $^{\rm TM}$  Microbiome Profile is a gut microbiota DNA analysis tool that identifies and characterizes more than 45 targeted analytes across six Phyla using PCR and compares the patient results to a characterized normobiotic reference population. The web chart illustrates the degree to which an individual's microbiome profile deviates from normobiosis.



#### LEGEND

The web image shows the relative diversity and balance among bacteria belonging to the six primary Phyla. The white shaded area represents the patient's results compared to a normobiotic reference population. The center of the web represents less abundance while the outer edges represent more than normobiotic.



### **Dysbiosis Index**

The Dysbiosis Index (DI) is a calculation with scores from 1 to 5 based on the overall bacterial abundance and profile within the patient's sample as compared to a reference population. Values above 2 indicate a microbiota profile that differs from the defined normobiotic reference population (i.e., dysbiosis). The higher the DI above 2, the more the sample is considered to deviate from normobiosis.





Expected Flora Summary	Key Findings
Clostridia Class, WRI	Salmonella spp., Detected
Bacteroides fragilis, WRI	Lactoferrin, Very High
Bacteroides spp. & Prevotella spp., WRI	Calprotectin, Very High
Bifidobacterium spp., WRI	Morganella morganii, Detected
Escherichia spp., WRI	Salmonella group, Detected
Lactobacillus spp., WRI	Yeast, Detected
	Candida albicans, Detected

#### Notes:



# Microbiome Bacterial Abundance; Multiplex PCR



Order:999999-9999

Client #:99999
Doctor:Sample Doctor
Sample Clinic
1234 Main St

Saint Charles, IL 60174 U.S.A.

Patient:SAMPLE PATIENT


ld:99999999

Age: 62 DOB: 01/12/1957

Sex: Male

Sample Collection
Date Collected
Date Received
Date Reported
Specimens Collected

**Date/Time** 09/23/2019 09/26/2019 10/10/2019



Results are graphed as deviations from a normobiotic population. Normobiosis or a normobiotic state characterizes a composition of the microbiota profile in which microorganisms with potential health benefits predominate in abundance and diversity over potentially harmful ones.

Result	-3	-2	-1	0	+1	+2	+3	Reference Interval
0				<b>A</b>				-1 to +1
0				<b>A</b>				0 to +1
0				<b>A</b>				-1 to +1
Result	-3	-2	-1	0	+1	+2	+3	Reference Interval
-1								-1 to +1
-1			A					-1 to +1
+1								0 to +1
0				<b>A</b>				-1 to +1
0				<b>A</b>				0 to +1
0				<b>A</b>				0 to +1
0				<b>A</b>				0 to +1
0				<b>A</b>				-1 to +1
Result	-3	-2	-1	0	+1	+2	+3	Reference Interval
0				<b>A</b>				-1 to +1
-1								-1 to +1
0				<b>A</b>				-1 to +1
+1								-1 to +1
0				<b>A</b>				-1 to +1
	0 0 Result -1 -1 +1 0 0 0 Result 0 -1 -1 0 +1	0 0 Result .3 -1 -1 +1 0 0 0 Result .3 0 -1 0 +1	0 0 Result -3 -2 -1 -1 +1 0 0 0 Result -3 -2 0 -1 0 +1	0 0 Result -3 -2 -1 -1 -1 -1 0 0 0 Result -3 -2 -1 0 -1 0 -1 0 -1 0 +1	0	0 0 0 Result	0 0 0 Result -3 -2 -1 0 +1 +2 -1	0 0 0 Result _3 _2 _1 _0 _+1 +2 +3 -1 -1 +1 0 0 0 Result _3 _2 _1 _0 _+1 +2 +3 0 0 0 0 0 0 Result _3 _2 _1 _0 _+1 +2 +3 0 -1 0 A

The gray-shaded area of the bar graph represents reference values outside the reporting limits for this test.

\*This test was developed and its performance characteristics determined by Doctor's Data Laboratories in a manner consistent with CLIA requirements. The U. S. Food and Drug Administration (FDA) has not approved or cleared this test; however, FDA clearance is not currently required for clinical use. The results are not intended to be used as a sole means for clinical diagnosis or patient management decisions.

Notes:

Methodology: Multiplex PCR



## Microbiome Bacterial Abundance; Multiplex PCR



Order:999999-9999

Client #:99999 Doctor:Sample Doctor

Sample Clinic 1234 Main St

Saint Charles, IL 60174 U.S.A.

Patient:SAMPLE PATIENT

ld:9999999

**Age:** 62 **DOB:** 01/12/1957

Sex: Male

Sample Collection
Date Collected
Date Received
Date Reported
Specimens Collected

**Date/Time** 09/23/2019 09/26/2019 10/10/2019

Firmicutes	Result	-3 -2	-1 0	+1 +2	+3	Reference Interval
Dialister invisus	0					0 to +1
Dialister invisus & Megasphaera micronuciformis	0		A			0 to +1
Dorea spp.	0		<b>A</b>			0 to +1
Eubacterium biforme	0					0 to +1
Eubacterium hallii	0		<b>A</b>			-1 to +1
Eubacterium rectale	0					0 to +1
Eubacterium siraeum	0		<b>A</b>			-1 to +1
Faecalibacterium prausnitzii	-2	Δ				-1 to +1
Lachnospiraceae	0		<b>A</b>			-1 to +1
Lactobacillus ruminis & Pediococcus acidilactici	0		<b>A</b>			0 to +1
Lactobacillus spp.	0					0 to +1
Phascolarctobacterium spp.	0					0 to +1
Ruminococcus albus & R. bromii	0					0 to +1
Ruminococcus gnavus	+3				<b>A</b>	0 to +1
Streptococcus agalactiae & Eubacterium rectale	0		<b>A</b>			0 to +1
Streptococcus salivarius ssp. thermophilus & S. sanguinis	0		<b>A</b>			-1 to +1
Streptococcus salivarius ssp. thermophilus	0					0 to +1
Streptococcus spp.	0					0 to +1
Veillonella spp.	0		<b>A</b>			-1 to +1

The gray-shaded area of the bar graph represents reference values outside the reporting limits for this test.

\*This test was developed and its performance characteristics determined by Doctor's Data Laboratories in a manner consistent with CLIA requirements. The U. S. Food and Drug Administration (FDA) has not approved or cleared this test; however, FDA clearance is not currently required for clinical use. The results are not intended to be used as a sole means for clinical diagnosis or patient management decisions.

Notes:

Methodology: Multiplex PCR



## Microbiome Bacterial Abundance; Multiplex PCR



Order:999999-9999

Client #:99999
Doctor:Sample Doctor

Sample Clinic 1234 Main St

Saint Charles, IL 60174 U.S.A.

Patient:SAMPLE PATIENT

ld:99999999

**Age:**62 **DOB:**01/12/1957

Sex: Male

Sample Collection Date Collected Date Received Date Reported

**Date/Time** 09/23/2019 09/26/2019 10/10/2019

Specimens Collected 2

Proteobacteria	Result	-3	-2	-1	0	+1	+2	+3	Reference Interval
Proteobacteria	0				<b>A</b>				0 to +1
Escherichia spp.	+1					<b>A</b>			-1 to +1
Tenericutes	Result	-3	-2	-1	0	+1	+2	+3	Reference Interval
Mycoplasma hominis	-1								-1 to +1
Verrucomicrobia	Result	-3	-2	-1	0	+1	+2	+3	Reference Interval
Akkermansia muciniphila	0				<b>A</b>				0 to +1



## **Microbiome Abundance Information:**

The GI360™ Microbiome Profile is a gut microbiota profiling test that characterizes patient results by determining deviation from a well-defined state of normobiosis using PCR. The profiling approach contrasts to direct diagnosis of a particular disease by detecting one organism. Characteristic sets of bacteria are required in a healthy normobiotic gut, and deviation will represent a potentially dysbiotic state. Measurement of deviation in bacterial microbiota makes it possible to characterize differences in the patient's results based on an established algorithm that defines normobiosis. By combining information from a well-defined set of predetermined PCR probes, this test enables highly reproducible and standardized information to be derived from the complex human microbiota. A summary web graphic chart is provided to represent bacterial abundance and diversity within a stool sample.


The gray-shaded area of the bar graph represents reference values outside the reporting limits for this test.

\*This test was developed and its performance characteristics determined by Doctor's Data Laboratories in a manner consistent with

CLIA requirements. The U. S. Food and Drug Administration (FDA) has not approved or cleared this test; however, FDA clearance is not currently required for clinical use. The results are not intended to be used as a sole means for clinical diagnosis or patient management decisions.



Methodology: Multiplex PCR







Client #:99999 Doctor:Sample Doctor Sample Clinic

1234 Main St Saint Charles, IL 60174 U.S.A. Patient:SAMPLE PATIENT

ld:9999999

**Age:**62 **DOB:**01/12/1957

Sex: Male

Sample Collection
Date Collected
Date Received
Date Reported

**Date/Time** 09/23/2019 09/26/2019 10/10/2019

Specimens Collected 2

Viruses	Result	
Adenovirus F40/41	Negative	
Norovirus GI/GII	Negative	
Rotavirus A	Negative	
Pathogenic Bacteria	Result	
Campylobacter (C. jejuni, C. coli and C. lari)	Negative	
Clostridium difficile (Toxin A/B)	Negative	
Escherichia coli O157	Negative	
Enterotoxigenic Escherichia coli (ETEC) lt/st	Negative	
Salmonella spp.	Positive	
Shiga-like toxin-producing Escherichia coli (STEC) stx1/stx2	Negative	
Shigella (S. boydii, S. sonnei, S. flexneri & S. dysenteriae)	Negative	
Vibrio cholerae	Negative	
Parasites	Result	
Cryptosporidium (C. parvum and C. hominis)	Negative	
Entamoeba histolytica	Negative	
Giardia duodenalis (AKA intestinalis & lamblia)	Negative	





Client #:99999
Doctor:Sample Doctor

Sample Clinic 1234 Main St

Saint Charles, IL 60174 U.S.A.

Patient:SAMPLE PATIENT

ld:9999999

**Age:**62 **DOB:**01/12/1957

Sex: Male

Sample Collection Date Collected 09
Date Received 09
Date Reported 10
Specimens Collected 2

**Date/Time** 09/23/2019 09/26/2019 10/10/2019

Protozoa	Result	
Balantidium coli	Not Detected	
Blastocystis spp.	Not Detected	
Chilomastix mesnili	Not Detected	
Dientamoeba fragilis	Not Detected	
Endolimax nana	Not Detected	
Entamoeba coli	Not Detected	
Entamoeba hartmanni	Not Detected	
Entamoeba histolytica/Entamoeba dispar	Not Detected	
Entamoeba polecki	Not Detected	
Enteromonas hominis	Not Detected	
Giardia duodenalis	Not Detected	
lodamoeba bütschlii	Not Detected	
Isospora belli	Not Detected	
Pentatrichomonas hominis	Not Detected	
Retortamonas intestinalis	Not Detected	
Cestodes - Tapeworms	Result	
Diphyllobothrium latum	Not Detected	
Dipylidium caninum	Not Detected	
Hymenolepis diminuta	Not Detected	
Hymenolepis nana	Not Detected	
Taenia	Not Detected	
Trematodes - Flukes	Result	
Clonorchis sinensis	Not Detected	
Fasciola hepatica/Fasciolopsis buski	Not Detected	
Heterophyes heterophyes	Not Detected	
Paragonimus westermani	Not Detected	
Nematodes - Round Worms	Result	
Ascaris lumbricoides	Not Detected	
Notes:		

Methodology: Microscopy





Client #:99999
Doctor:Sample Doctor
Sample Clinic
1234 Main St
Saint Charles, IL 60174 U.S.A.

Patient:SAMPLE PATIENT

ld:9999999

Age: 62 DOB: 01/12/1957

Sex: Male

Sample Collection
Date Collected
Date Received
Date Reported
Specimens Collected

Date/Time 09/23/2019 09/26/2019 10/10/2019

Nematodes - Round Worms	Result	
Capillaria hepatica	Not Detected	
Capillaria philippinensis	Not Detected	
Enterobius vermicularis	Not Detected	
Hookworm	Not Detected	
Strongyloides stercoralis	Not Detected	
Trichuris trichiura	Not Detected	
Other Markers	Result	Reference Interval
Yeast	Many	Not Detected – Rare
RBC	Not Detected	Not Detected – Rare
WBC	Not Detected	Not Detected – Rare
Muscle fibers	Not Detected	Not Detected – Rare
Vegetable fibers	Rare	Not Detected – Few
Charcot-Leyden Crystals	Not Detected	Not Detected
Pollen	Not Detected	Not Detected
Macroscopic Appearance	Result	Reference Interval
Color	Brown	Brown
Consistency	Soft	Soft
Mucus	Negative	Negative

### GI 360

## Parasitology Information:

- One negative parasitology x1 specimen does not rule out the possibility of parasitic disease, parasitology x3 is recommended. This test is not designed to detect *Cyclospora cayetanensis* or *Microsproridia* spp.
- Intestinal parasites are abnormal inhabitants of the gastrointestinal tract that have the potential to cause damage to their host. The presence of any parasite within the intestine generally confirms that the patient has acquired the organism through fecal-oral contamination. Damage to the host includes parasitic burden, migration, blockage and pressure. Immunologic inflammation, hypersensitivity reactions and cytotoxicity also play a large role in the morbidity of these diseases. The infective dose often relates to severity of the disease and repeat encounters can be additive.
- There are two main classes of intestinal parasites, they include protozoa and helminths. The protozoa typically have two stages; the trophozoite stage that is the metabolically active, invasive stage and the cyst stage, which is the vegetative inactive form resistant to unfavorable environmental conditions outside the human host. Helminths are large, multicellular organisms. Like protozoa, helminths can be either free-living or parasitic in nature. In their adult form, helminths cannot multiply in humans.

#### Notes:



Client #:99999
Doctor:Sample Doctor
Sample Clinic
1234 Main St
Saint Charles, IL 60174 U.S.A.

Patient:SAMPLE PATIENT


ld:99999999

Age: 62 DOB: 01/12/1957

Sex: Male

Sample Collection Date/Time
Date Collected 09/23/2019
Date Received 09/26/2019
Date Reported 10/10/2019
Specimens Collected 2

- In general, acute manifestations of parasitic infection may involve diarrhea with or without mucus and or blood, fever, nausea, or abdominal pain. However these symptoms do not always occur. Consequently, parasitic infections may not be diagnosed or eradicated. If left untreated, chronic parasitic infections can cause damage to the intestinal lining and can be an unsuspected cause of illness and fatigue. Chronic parasitic infections can also be associated with increased intestinal permeability, irritable bowel syndrome, irregular bowel movements, malabsorption, gastritis or indigestion, skin disorders, joint pain, allergic reactions, and decreased immune function.
- In some instances, parasites may enter the circulation and travel to various organs causing severe organ diseases such as liver abscesses and cysticercosis. In addition, some larval migration can cause pneumonia and in rare cases hyper infection syndrome with large numbers of larvae being produced and found in every tissue of the body.
- Red Blood Cells (RBC) in the stool may be associated with a parasitic or bacterial infection, or an inflammatory bowel condition such as ulcerative colitis. Colorectal cancer, anal fistulas, and hemorrhoids should also be ruled out.
- White Blood Cells (WBC) and Mucus in the stool can occur with bacterial and parasitic infections, with mucosal irritation, and inflammatory bowel diseases such as Crohn's disease or ulcerative colitis
- Muscle fibers in the stool are an indicator of incomplete digestion. Bloating, flatulence, feelings of "fullness" may be associated with increase in muscle fibers.
- Vegetable fibers in the stool may be indicative of inadequate chewing, or eating "on the run".
- Color: Stool is normally brown because of pigments formed by bacteria acting on bile introduced into the digestive system from the liver. While certain conditions can cause changes in stool color, many changes are harmless and are caused by pigments in foods or dietary supplements.
- **Consistency:** Stool normally contains about 75% water and ideally should be formed and soft. Stool consistency can vary based upon transit time and water absorption.







Client #:99999
Doctor:Sample Doctor
Sample Clinic
1234 Main St
Saint Charles, IL 60174 U.S.A.

Patient:SAMPLE PATIENT

ld:9999999

Age: 62 DOB: 01/12/1957

Sex: Male

Sample Collection
Date Collected
Date Received
Date Reported
Specimens Collected

**Date/Time** 09/23/2019 09/26/2019 10/10/2019

Pathogenic Bacteria	Result	NG	1+	2+	3+	4+	Reference Interval
Aeromonas spp.	NG						No Growth
Edwardsiella tarda	NG						No Growth
Plesiomonas shigelloides	NG						No Growth
Salmonella group	2+						No Growth
Shigella spp.	NG						No Growth
Vibrio cholerae	NG						No Growth
Vibrio spp	NG						No Growth
Yersinia spp.	NG						No Growth
Imbalance Bacteria	Result	NG	1+	2+	3+	4+	Reference Interval
Alpha hemolytic strep	4+					Δ	No Growth
Gamma hemolytic strep	3+				Δ		No Growth
Staphylococcus aureus	2+			Δ			No Growth
Dysbiotic Bacteria	Result	NG	1+	2+	3+	4+	Reference Interval
Morganella morganii	4+						No Growth
Yeast	Result	NG	1+	2+	3+	4+	Reference Interval
Candida albicans	2+						0+ - 1+



## **Microbiology Information:**

- Pathogenic bacteria consist of known pathogenic bacteria that can cause disease in the GI tract. They are present due to the consumption of contaminated food or water, exposure to animals, fish, or amphibians known to harbor the organism. These organisms can be detected by either Multiplex PCR or microbiology culture.
- **Imbalanced bacteria** are usually neither pathogenic nor beneficial to the host GI tract. Imbalances can occur when there are insufficient levels of beneficial bacteria and increased levels of commensal bacteria. Certain commensal bacteria are reported as dysbiotic at higher levels.
- **Dysbiotic bacteria** consist of those bacteria that have the potential to cause disease in the GI tract. They can be present due to a number of factors including: exposure to chemicals that are toxic to beneficial bacteria; the use of antibiotics, oral contraceptives or other medications; poor fiber intake and high stress levels.







Client #:99999 Doctor:Sample Doctor Sample Clinic 1234 Main St

Saint Charles, IL 60174 U.S.A.

Patient:SAMPLE PATIENT

ld:9999999

Age: 62 DOB: 01/12/1957

Sex: Male

Sample CollectionDate/TimeDate Collected09/23/2019Date Received09/26/2019Date Reported10/10/2019Specimens Collected2

Yeast may normally be present in small quantities in the skin, mouth, and intestine. When investigating the presence of yeast, disparity may exist between culturing and microscopic examination. Yeast are not uniformly dispersed throughout the stool and this may lead to undetectable or low levels of yeast identified by microscopy, despite culture and identified yeast species. Conversely, microscopic examination may reveal a significant amount of yeast present but no viable yeast cultured. Yeast may not always survive transit through the intestines. Nonviable diet-derived yeast may also be detected microscopically. Consideration of clinical intervention for yeast detected microscopically should be made in the context of other findings and presentation of symptoms.









Client #:99999

Doctor:Sample Doctor

Sample Clinic 1234 Main St

Saint Charles, IL 60174 U.S.A.

Patient:SAMPLE PATIENT

ld:99999999

Age: 62 DOB: 01/12/1957

Sex: Male

Sample Collection
Date Collected
Date Received
Date Reported
Specimens Collected

**Date/Time** 09/23/2019 09/26/2019 10/10/2019

Natural Agents	Low Susceptibility		High Susceptibility
Berberine			
Black Walnut			
Caprylic Acid		$\triangle$	
Grapefruit Seed Extract			A
Oregano			
Silver			A
Uva Ursi			<b>A</b>

Prescriptive Agents	Resistant	Intermediate	Susceptible	
Ampicillin				
Ciprofloxacin				
Sulfamethoxazole / Trimethoprim				



## **Susceptibility Information:**

- Natural antibacterial agents may be useful for treatment of patients when organisms display in-vitro susceptibility to these agents. The test is performed by using standardized techniques and filter paper disks impregnated with the listed agent. Relative susceptibility is reported for each natural agent based upon the diameter of the zone of inhibition surrounding the disk. Data based on over 5000 individual observations were used to relate the zone size to the activity level of the agent. A scale of relative susceptibility is defined for the natural agents tested.
- Susceptible results imply that an infection due to the bacteria may be appropriately treated when the recommended dosage of the tested antimicrobial agent is used. Intermediate results imply that response rates may be lower than for susceptible bacteria when the tested antimicrobial agent is used. Resistant results imply that the bacteria will not be inhibited by normal dosage levels of the tested antimicrobial agent.



\*Natural antibacterial agent susceptibility testing was developed and its performance characteristics determined by Doctor's Data Laboratories in a manner consistent with CLIA requirements. The U. S. Food and Drug Administration (FDA) has not approve or cleared this test; however, FDA clearance is not currently required for clinical use. The results are not intended to be used as a sole means for clinical diagnosis or patient management decisions.

Notes:





Client #:99999 Doctor:Sample Doctor Sample Clinic

Sample Clinic 1234 Main St

Saint Charles, IL 60174 U.S.A.

Patient:SAMPLE PATIENT

ld:99999999

Age: 62 DOB: 01/12/1957


Sex: Male

Sample Collection
Date Collected
Date Received
Date Reported

**Date/Time** 09/23/2019 09/26/2019 10/10/2019

Specimens Collected 2

Natural Agents	Low Susceptibility		High Susceptibility
Berberine			
Black Walnut			
Caprylic Acid			
Grapefruit Seed Extract			<u> </u>
Oregano			
Silver			<b>A</b>
Uva Ursi			
Prescriptive Agents	Resistant	Intermediate	Susceptible
Amoxicillin-Clavulanic Acid			
Ampicillin			
Cefazolin			
Ceftazidime			
Ciprofloxacin			
Sulfamethoxazole / Trimethoprim			



- Natural antibacterial agents may be useful for treatment of patients when organisms display in-vitro susceptibility to these
  agents. The test is performed by using standardized techniques and filter paper disks impregnated with the listed agent. Relative
  susceptibility is reported for each natural agent based upon the diameter of the zone of inhibition surrounding the disk. Data
  based on over 5000 individual observations were used to relate the zone size to the activity level of the agent. A scale of relative
  susceptibility is defined for the natural agents tested.
- Susceptible results imply that an infection due to the bacteria may be appropriately treated when the recommended dosage of the tested antimicrobial agent is used. Intermediate results imply that response rates may be lower than for susceptible bacteria when the tested antimicrobial agent is used. Resistant results imply that the bacteria will not be inhibited by normal dosage levels of the tested antimicrobial agent.



\*Natural antibacterial agent susceptibility testing was developed and its performance characteristics determined by Doctor's Data Laboratories in a manner consistent with CLIA requirements. The U. S. Food and Drug Administration (FDA) has not approve or cleared this test; however, FDA clearance is not currently required for clinical use. The results are not intended to be used as a sole means for clinical diagnosis or patient management decisions. **Notes:** 





Client #:99999
Doctor:Sample Doctor
Sample Clinic
1234 Main St

Saint Charles, IL 60174 U.S.A.

Patient:SAMPLE PATIENT

ld:99999999

Age: 62 DOB: 01/12/1957


Sex: Male

Sample Collection
Date Collected
Date Received
Date Reported

**Date/Time** 09/23/2019 09/26/2019 10/10/2019

Specimens Collected 2

Natural Agents	Low Susceptibility		High Susceptibility
Berberine			
Caprylic Acid			
Grapefruit Seed Extract			
Oregano			
Plant Tannins			
Undecylenic Acid		Δ	
Uva Ursi		7	
Non-Absorbed Antifungals	Low Susceptibility		High Susceptibility
Nystatin			
Azole Antifungals	Resistant	S-DD	Susceptible
Fluconazole			
Ketoconazole			



- Natural antifungal agents may be useful for treatment of patients when organisms display in-vitro susceptibility to these agents. The test is performed by using standardized techniques and filter paper disks impregnated with the listed agent. Relative activity is reported for each natural agent based upon the diameter of the zone of inhibition or no growth zone surrounding the disk. Data based on over 5000 individual observations were used to relate the zone size to the activity level of the agent. A scale of relative activity is defined for the natural agents tested.
- **Non-absorbed antifungals** may be useful for treatment of patients when organisms display in-vitro susceptibility to these agents. The test is performed using standardized commercially prepared disks impregnated with Nystatin. Relative activity is reported based upon the diameter of the zone of inhibition or no growth zone surrounding the disk.
- Susceptible results imply that an infection due to the fungus may be appropriately treated when the recommended dosage of the tested antifungal agent is used. Susceptible Dose Dependent (S-DD) results imply that an infection due to the fungus may be treated when the highest recommended dosage of the tested antifungal agent is used. Resistant results imply that the fungus will not be inhibited by normal dosage levels of the tested antifungal agent.

